MannKind Corporation (MNKD)

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum

Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

MannKind to Present at Upcoming Investor Conferences

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

MannKind: New Approvals Majorly Increase MannKind's Prospects

MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript

MannKind Q2 Earnings Call Highlights

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript

MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway

MannKind injection helps heart failure patients avoid ER infusions

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy?

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript